PlGF Isoform Ratio Analysis for Preeclampsia Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective early detection of pre-eclampsia, a leading cause of maternal death, with no routine screens for early detection using maternal samples, and existing markers like PlGF have limitations in specificity and predictive power.
Innovation Solution
The method involves determining the levels of PlGF isoforms (PlGF-2 and PlGF-3) in maternal samples, comparing them to control samples, and using ratios of these isoforms with other biochemical and biophysical markers to assess the risk or presence of pre-eclampsia, employing specific antibodies and kits for accurate detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PlGF is used as a marker for pre-eclampsia risk assessment, then the detection capability is improved, but the specificity and predictive power are insufficient
Solution Approach 1:
The patent segments the PlGF marker into multiple isoforms (PlGF-1, PlGF-2, PlGF-3) and measures them individually rather than as a single marker. This segmentation allows for more specific risk assessment by evaluating the unique patterns of each isoform, thereby improving both detection capability and predictive power for pre-eclampsia
Solution Approach 2:
The patent combines multiple PlGF isoforms into a composite marker profile for risk assessment. By integrating the information from PlGF-1, PlGF-2, and PlGF-3 into a unified assessment model, the method achieves higher reliability and predictive power than using any single isoform alone
2Device complexity
If no routine screening is performed, then the complexity of healthcare procedures is reduced, but early detection capability is lost
Solution Approach 1:
The patent develops a universal screening method that can be applied to all pregnant women regardless of risk factors. The multi-functional assay simultaneously measures multiple PlGF isoforms and can be integrated into routine prenatal care, providing early detection capability without significantly increasing procedural complexity
Solution Approach 2:
The patent changes the measurement parameters from single-marker assessment to multi-isoform profiling. By measuring the levels and ratios of different PlGF isoforms, the method enables early detection with improved accuracy while maintaining feasibility for routine screening through standardized assay protocols
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably PlGF-2 and PlGF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.